Disc Medicine, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Disc Medicine, Inc. (IRON) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $266.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-07-30
- Disc Medicine, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $114.36M, a 3.63% increase year-over-year.
- Disc Medicine, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $152.07M, a 101.50% increase year-over-year.
- Disc Medicine, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $135.40M, a 88.58% increase year-over-year.
- Disc Medicine, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $135.00M, a 486.96% increase year-over-year.
- Disc Medicine, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $456.22M, a 381.24% increase from fiscal 2024.
- Disc Medicine, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $94.80M.
- Disc Medicine, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $0.00.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $114.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $266.43M 10-Q · filed 2026-07-30 | $401.83M derived: sum of 3 quarters · filed 2026-07-30 | $536.83M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $152.07M 10-Q · filed 2026-05-05 | $287.47M derived: sum of 2 quarters · filed 2026-05-05 | $422.47M derived: sum of 3 quarters · filed 2026-05-05 | $532.82M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $135.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $270.40M derived: sum of 2 quarters · filed 2026-02-26 | $380.75M derived: sum of 3 quarters · filed 2026-07-30 | $456.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | $135.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $245.35M derived: sum of 2 quarters · filed 2026-07-30 | $320.82M 10-Q · filed 2025-11-06 | $392.62M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $110.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $185.82M 10-Q · filed 2026-07-30 | $257.62M derived: sum of 3 quarters · filed 2026-07-30 | $280.62M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $75.47M 10-Q · filed 2026-05-05 | $147.27M derived: sum of 2 quarters · filed 2026-05-05 | $170.27M derived: sum of 3 quarters · filed 2026-05-05 | $170.27M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $71.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $94.80M derived: sum of 2 quarters · filed 2026-02-26 | $94.80M derived: sum of 3 quarters · filed 2026-02-26 | $94.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $23.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $23.00M derived: sum of 2 quarters · filed 2025-11-06 | $23.00M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |